-
OncoTargets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
OncoTargets and Therapy
(390,640) Views
1178-6930
ISSN: 1178-6930
An international, peer-reviewed journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. In terms of therapy, palliative care is also included as part of the overall patient care process. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. This journal explores the evidence behind new and existing therapies in terms of improving outcomes and, importantly, will seek to define their usage in terms of ultimate uptake and acceptance by the patient and health care professional.
Journal Impact Factor: 0.176
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Indexed online:
- PubMed (Onco Targets Ther)
- EMBase
- Scopus
- Directory of Open Access Journals (DOAJ)
- OAIster: The Open Access Initiative
- ResearchGATE scientific network
Article Processing Statistics:
10 From submission of manuscript to first editorial decision (including peer-review)
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Intranet access to all Dove journals
If you would like your institutional intranet to have access to the Dove Medical Press journals please contact me.




